Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 16/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17296432 | 0.98 | SIGMAR1 (0.49) | SIGMAR1KCNH2KDRMETDRD2 | |
| SCHEMBL18750530 | 0.83 | SIGMAR1 (0.54) | SIGMAR1KDRMET | |
| SCHEMBL17307860 | 0.82 | LIMK1 (0.63) | SIGMAR1KDRMET | |
| SCHEMBL14422090 | 0.79 | SIGMAR1 (0.51) | SIGMAR1KCNH2KDRMETDRD2 | |
| SCHEMBL735589 | 0.78 | LIMK1 (0.66) | KDRDRD2 | |
| SCHEMBL11742 | 0.78 | LIMK1 (0.66) | DRD2 | |
| SCHEMBL938557 | 0.74 | KDR (0.65) | KDRMET | |
| SCHEMBL15140475 | 0.74 | LIMK1 (0.42) | DRD2 | |
| SCHEMBL12908954 | 0.73 | KDR (0.56) | KDRMET | |
| SCHEMBL6315989 | 0.73 | LIMK1 (0.69) | KDRMETDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| WO-2015181063-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-03 | — | — | WO | disclosed |
| US-8501755-B2 | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8501755-B2 | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8501755-B2 | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-2001890-B1 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND USE FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | BAYER SCHERING PHARMA AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| EP-2001890-B1 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND USE FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | BAYER SCHERING PHARMA AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-11-25 | — | — | US | disclosed |
| WO-2007109279-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | TYMP, DPYD, TYMS | SIGMAR1 4768/4885KCNH2 4584/4885KDR 53/4885 |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | DPYD, TYMP, TPMT | SIGMAR1 3990/4885KCNH2 3383/4885KDR 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.